What 503A Compounding Means for Your GLP-1 Medication

If you’ve been prescribed a compounded GLP-1 medication like semaglutide or tirzepatide, you may have seen the term “503A compounding pharmacy” and wondered what it actually means. Here’s the honest version, in plain language: what patient-specific compounding is, how a state-licensed 503A pharmacy operates, how to verify a pharmacy is legitimate, and how Contour sources its compounded medications through the WellSync network.

What a 503A Compounding Pharmacy Is

A 503A pharmacy is the traditional compounding pharmacy. The “503A” designation comes from section 503A of the federal Food, Drug, and Cosmetic Act, which establishes the legal framework for patient-specific compounding.

When a licensed clinician writes a prescription tailored to one individual patient, a 503A pharmacy prepares that medication for that specific person.

What defines a 503A compounding pharmacy:

• It compounds for a specific patient based on a valid, patient-specific prescription — not for a shelf or a stock room.
• It is licensed and overseen primarily by the state board of pharmacy in the state where it operates. The state board can inspect, discipline, or revoke the pharmacy’s license.
• It is expected to follow United States Pharmacopeia (USP) standards for sterile and non-sterile preparation — including USP <797> for sterile compounding (such as injectable medications) and USP <795> for non-sterile preparations — covering quality, testing, and beyond-use dating.
• Its preparations usually carry shorter beyond-use dates, reflecting the made-to-order nature of patient-specific production.
• It is not a drug manufacturer and does not operate under the same regulatory framework as a drug manufacturer.

The strength of the 503A model is exactly that it is patient-specific. The medication is prepared to match what a clinician determined one particular patient needs — which, for personalized GLP-1 care, is the whole point.

How Patient-Specific Compounding Works

“Compounding” means a pharmacy prepares a medication rather than dispensing it pre-packaged from a drug manufacturer. For a 503A pharmacy, every preparation begins with a valid prescription written for a named, identified patient.

Under section 503A, a compounded drug generally may not be essentially a copy of a commercially available, FDA-approved product. The key exception: when the prescribing clinician determines, for a specific patient, that the compounded version produces a significant difference compared to the approved product — and documents that clinical rationale.

That determination must be a genuine clinical judgment made for one individual. It is not a mechanism for providing a lower-cost version of a brand-name drug. The durable, legitimate reason to compound a GLP-1 medication is that a clinician decided your care calls for something the standard commercial product does not offer for you specifically.

Personalization is the legal and clinical reason patient-specific compounding exists at all. It only works when a licensed clinician makes and documents the determination that a compounded version is appropriate for you. It is never a do-it-yourself decision, and it is not a way to self-select a dose or milligram strength.

What “Not FDA-Approved” Means — and Why It Matters

This is the most misunderstood point in this category, so it is worth being direct.

Compounded semaglutide and tirzepatide are not FDA-approved drugs. The FDA does not approve the individual preparations made by compounding pharmacies. In the FDA’s own words: “Compounded drugs are not approved by FDA.”

FDA-approved drugs go through a rigorous premarket review process for safety, effectiveness, and manufacturing quality. Compounded drugs qualify for legal exemptions from certain requirements — not approval.

Compounded GLP-1 medications are also not equivalent to, and not interchangeable with, commercially available FDA-approved products such as Ozempic, Wegovy, Mounjaro, or Zepbound. They are not the same drug. Individual results vary and are not guaranteed. A state board license and a pharmacy’s quality testing reflect oversight of the pharmacy and its processes — not FDA approval of the medication itself.

If you encounter marketing language suggesting that a compounded GLP-1 is FDA-approved or equivalent to a brand-name product, treat that as a red flag.

How to Verify a 503A Pharmacy’s Legitimacy

Not all compounding pharmacies operate to the same standard. Here is what to look for and ask:

1. State board of pharmacy license. Every legitimate 503A pharmacy holds a current license from the state board of pharmacy in the state where it operates. Most state boards maintain a public license lookup tool. Confirm that the pharmacy dispensing your prescription is licensed and in good standing.

2. NABP accreditation. The National Association of Boards of Pharmacy (NABP) offers a PCAB (Pharmacy Compounding Accreditation Board) accreditation program for compounding pharmacies that meet rigorous quality and safety standards. Accreditation is not required, but it is a meaningful signal of a pharmacy that has invited independent review of its practices.

3. USP standards compliance. Ask whether the pharmacy follows USP <797> for sterile compounding and USP <795> for non-sterile preparations. Reputable pharmacies can speak to their sterile practices, cleanroom standards, and quality assurance procedures.

4. Certificate of analysis (COA). A COA is documentation from third-party or in-house testing confirming a batch’s identity, potency, and purity. A pharmacy that takes quality seriously can typically provide a COA for your specific medication. This is one of the most direct ways to verify that testing is actually happening.

5. Active pharmaceutical ingredient (API) sourcing. The semaglutide or tirzepatide itself — the API — should come from an FDA-registered supplier. A reputable pharmacy can tell you where its API is sourced.

6. Transparent answers from your provider. Ask directly: Which pharmacy fills my prescription? Is it currently licensed by its state board? Can I see a COA? A trustworthy provider answers these questions plainly. Vague or deflective responses are a signal worth taking seriously.

How Contour Sources Its Compounded GLP-1 Medications

Contour’s compounded GLP-1 medications are prescribed by licensed clinicians and filled by WellSync and other state-licensed 503A compounding pharmacies in the WellSync network, pursuant to a valid patient-specific prescription.

We qualify pharmacies in our network based on state licensing status, adherence to USP sterile compounding standards, third-party testing practices, and API sourcing. We are glad to tell you which pharmacy fills your prescription and to share information about how that pharmacy is tested and vetted.

We are not going to tell you that a state license or quality testing is the same as FDA approval — it is not, and you deserve the accurate version. What we will tell you: who makes your medication, how we qualify the pharmacies we work with, and whether compounded care is the right choice for you in the first place. If it is not, we will say so. That is the value of having a real clinician in the loop.

See how Contour sources and tests compounded medications →

The Compounding Landscape as of 2026

The regulatory context for compounded GLP-1 medications has shifted, and some information online has not caught up.

For a period, compounded GLP-1s were widely available because semaglutide and tirzepatide appeared on the FDA’s drug shortage list, which created a broad legal pathway for compounding. That window has narrowed. The FDA determined the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. In April 2026, the FDA proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the bulks substances list for outsourcing facilities, citing no clinical need for these drugs to be compounded from bulk substance at that level.

Patient-specific 503A compounding by state-licensed pharmacies, pursuant to a valid prescription and a clinician’s documented clinical rationale, remains a recognized pathway — grounded in the patient-specific personalization purpose that section 503A was designed to serve.

If you are reading older content suggesting compounding is justified primarily by the shortage, that rationale is out of date. The current, durable reason compounding retains a legitimate place is the patient-specific, clinician-directed personalization that 503A exists to provide.

Frequently Asked Questions

What is a 503A compounding pharmacy?

A 503A compounding pharmacy is a state-licensed pharmacy that prepares medications for individual patients based on a valid, patient-specific prescription. The designation comes from section 503A of the federal Food, Drug, and Cosmetic Act. These pharmacies are overseen primarily by state boards of pharmacy and are expected to follow USP standards for sterile and non-sterile compounding.

Is a compounded GLP-1 medication FDA-approved?

No. Compounded drugs — including compounded semaglutide and tirzepatide — are not FDA-approved. The FDA does not approve the individual preparations made by compounding pharmacies. Compounded GLP-1 medications are also not equivalent to and not interchangeable with FDA-approved brand-name products such as Ozempic, Wegovy, Mounjaro, or Zepbound. They are prepared for a specific patient under a licensed clinician’s direction, and individual results vary.

How do I know if a compounding pharmacy is legitimate?

Look for: a current state board of pharmacy license (verify through the state board’s public license lookup); NABP/PCAB accreditation if available; confirmation that the pharmacy follows USP sterile compounding standards; a certificate of analysis (COA) for your medication confirming identity, potency, and purity; and transparency about API sourcing. A trustworthy provider will answer these questions directly.

What does “significant difference” mean for a compounded GLP-1 prescription?

Under 503A, a clinician may determine that a compounded preparation produces a significant difference compared to the commercially available product for a specific patient — and document that clinical rationale. This is a genuine clinical judgment made for an individual. It is not a general workaround for cost or preference. The prescribing clinician must make and document this determination; it is not something a patient selects.

Where does Contour get its compounded GLP-1 medications?

Contour’s compounded GLP-1 medications are filled by WellSync and other state-licensed 503A compounding pharmacies in the WellSync network, pursuant to a valid patient-specific prescription written by a licensed clinician. Pharmacies in the network are vetted on state licensing, USP standards compliance, third-party testing practices, and API sourcing.

Can I choose my dose of compounded semaglutide?

No. Dosing for compounded GLP-1 medications is determined by your clinician based on your individual clinical needs and history. Clinician-directed dosing is a fundamental requirement of safe, legal, patient-specific compounded care.

Can compounding pharmacies still make semaglutide and tirzepatide now that the shortages are over?

The FDA determined the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. In April 2026, the FDA proposed to permanently exclude both drugs from the bulks substances list for outsourcing facilities. Patient-specific 503A compounding by a state-licensed pharmacy can still occur when a licensed clinician documents that an individual patient needs a compounded version that produces a significant difference from the commercial product. That is a clinical decision made for a specific patient — not a general availability.

Related Articles

• Compounded Semaglutide Safety: What to Know
• Is Compounded Semaglutide FDA-Approved?
• Complete Guide to Semaglutide
• Microdosing Semaglutide: What to Know

Medical Disclaimer